Skip to main content

Chemical Injury

0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

City Therapeutics
City TherapeuticsMA - Cambridge
1 program
Clinical interventions performed in acute settingsN/A
Defence Therapeutics
Defence TherapeuticsBC - Vancouver
1 program
Clinical interventions performed in acute settingsN/A1 trial
Active Trials
NCT05026645Enrolling By Invitation1,000Est. Dec 2036

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Defence TherapeuticsClinical interventions performed in acute settings

Clinical Trials (1)

Total enrollment: 1,000 patients across 1 trials

NCT05026645Defence TherapeuticsClinical interventions performed in acute settings

The Medical Management in Patients Exposed to Weapons of Mass Destruction

Start: Oct 2020Est. completion: Dec 20361,000 patients
N/AEnrolling By Invitation

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.